Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond by Wolfgang Löscher et al.
REVIEW ARTICLE
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment
of Epilepsy and Beyond
Wolfgang Lo¨scher1,2 • Michel Gillard3 • Zara A. Sands3 • Rafal M. Kaminski3 •
Henrik Klitgaard3
Published online: 17 October 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract The synaptic vesicle glycoprotein SV2A belongs to
themajor facilitator superfamily (MFS)of transporters and is an
integral constituent of synaptic vesicle membranes. SV2A has
been demonstrated to be involved in vesicle trafficking and
exocytosis, processes crucial for neurotransmission. The anti-
seizure drug levetiracetam was the first ligand to target SV2A
and displays a broad spectrumof anti-seizure activity in various
preclinical models. Several lines of preclinical and clinical
evidence, including genetics and protein expression changes,
support an important role of SV2A in epilepsy pathophysiol-
ogy. While the functional consequences of SV2A ligand
binding are not fully elucidated, studies suggest that subsequent
SV2A conformational changes may contribute to seizure pro-
tection. Conversely, the recently discovered negative SV2A
modulators, such as UCB0255, counteract the anti-seizure
effect of levetiracetam and display procognitive properties in
preclinical models. More broadly, dysfunction of SV2A may
also be involved in Alzheimer’s disease and other types of
cognitive impairment, suggesting potential novel therapies for
levetiracetam and its congeners. Furthermore, emerging data
indicate that there may be important roles for two other SV2
isoforms (SV2B and SV2C) in the pathogenesis of epilepsy, as
well as other neurodegenerative diseases. Utilization of
recently developed SV2A positron emission tomography
ligands will strengthen and reinforce the pharmacological evi-
dence that SV2A is a druggable target, andwill provide a better
understanding of its role in epilepsy and other neurological
diseases, aiding in further defining the full therapeutic potential
of SV2A modulation.
Key Points
Synaptic vesicle glycoprotein SV2A is involved in
vesicle trafficking and exocytosis, and appears to
exert a role in epilepsy pathophysiology.
Levetiracetam was the first anti-seizure drug to target
SV2A, followed by brivaracetam, which selectively
targets SV2A.
SV2A and its isoforms, SV2B and SV2C, may also
be involved in the pathogenesis of other
neurodegenerative diseases, including Alzheimer’s
disease.
The recent identification of SV2A positron emission
tomography tracer ligands and selective SV2A
ligands that activate, antagonize and modulate the
function of SV2A should facilitate a further
understanding of the function and therapeutic
potential of SV2A.
1 Introduction
Epilepsy is the most common neurological condition affecting
individuals of all ages and a cause of substantial morbidity and
mortality [1, 2]. The mainstay of epilepsy therapy is the pro-
phylactic use of anti-seizure drugs (ASDs; also commonly
known as anticonvulsant or antiepileptic drugs [AEDs]), which
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provide symptomatic treatment of spontaneously recurrent
seizures, the predominant symptom of underlying epilepsy [3].
Available ASDs thus target mechanisms associated with sei-
zure generation and propagation (or ictogenesis) in the epileptic
brain. Although the approximately 20 clinically used ASDs act
by a variety of mechanisms (Fig. 1), they all act to reduce
hyperexcitability by either decreasing excitatory or enhancing
inhibitory neurotransmission. This involves modulation of
voltage-gated ion channels, enhancement of c-aminobutyric
acid (GABA)-mediated inhibition, interactions with elements
of the synaptic release machinery, or blockade of ionotropic
glutamate receptors [4, 5]. However, approximately 30 % of
patientswith epilepsy are not controlled by currentmedications
[3] and, despite a high prevalence of acquired epilepsy, no
preventive treatment exists for patients at risk of developing
epilepsy [3]. Thus, novel treatments for the pharmacoresistant
patient and the prevention of epilepsy are major unmet clinical
needs [3].
The processes underlying epileptogenesis (the development
of epilepsy following brain injury or other predisposing factors)
and pharmacoresistance are complex and likely reflect multi-
factorial phenomena, involving alterations in networks rather
than in single targets [3]. This emphasizes the therapeutic
promise of druggable targets that regulate multiple molecular
pathways (‘master regulators’), which may be driving these
molecular and physiological alterations. This review focusses
on the synaptic vesicle glycoprotein SV2A,which is thought to
be involved in vesicle function and neurotransmitter release in
normal and pathological brain conditions, and is altered during
epileptogenesis and in pharmacoresistant epilepsy. In addition,
there is increasing evidence that SV2Amay constitute amaster
regulator in different disease processes, including epilepsy (see
Sect. 3.4). Importantly, SV2A is the primary molecular target
of the ASD levetiracetam [6, 7] and the selective SV2A ligand
brivaracetam [8].The latterwas recently approved inEuropeby
the European Medicines Agency (EMA) and in the US by the
Food and Drug Administration (FDA) as adjunctive treatment
for drug refractory partial-onset seizures in patients with epi-
lepsy aged 16 years and above [9]. These drugs have not only
contributed a further understanding of the functions of SV2A
but also constitute a new category of highly effective and well
tolerated ASDs that have led to a paradigm shift in ASD
discovery.
2 The Discovery of Levetiracetam and its Effect
on SV2A
The discovery of the anti-seizure efficacy of levetiracetam
is an example of a successful joint endeavor between
academia and the industry. Levetiracetam, initially termed
ucb L059, is the S-enantiomer of the ethyl analog of
Fig. 1 Mechanism of action of clinically approved anti-seizure drugs.
Updated and modified from Lo¨scher and Schmidt [151]. Drugs marked
with asterisks indicate that these compounds act by multiple mechanims
(not all mechanisms shown here). GABA-T GABA aminotransferase,
GAT GABA transporter, SV2A synaptic vesicle protein 2A, GABA
gamma-aminobutyric acid, NMDA N-methyl-D-aspartate, AMPA a-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, KCNQ a family
of voltage-gated potassium channels (also known as the Kv7 family)
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piracetam (Fig. 2), a nootropic drug that is indicated for
cortical myoclonus, cerebrovascular insufficiencies, and
age-associated cognitive impairment. Levetiracetam was
discovered in 1977 at UCB Pharma in Belgium during
research to identify a second-generation nootropic agent to
replace piracetam [10]; however, levetiracetam failed to
show significant clinical activity in patients with cognitive
impairment. Instead, subsequent pharmacological testing
with levetiracetam showed seizure suppression in the
audiogenic seizure-susceptible DBA/2 mice, a genetic
animal model of epilepsy [11]. These and other findings
triggered UCB Pharma to commission Lo¨scher, in 1989, to
perform a further characterization of the anti-seizure effi-
cacy of levetiracetam in the amygdala kindling model, a
predictive rat model of temporal lobe epilepsy (TLE) [12].
For comparison, levetiracetam was also evaluated in the
maximal electroshock seizure (MES) and subcutaneous
pentylenetetrazole seizure tests [12], used as initial screens
in many ASD discovery programs at that time, including
the Anticonvulsant Screening Program (ASP) of the
National Institute of Neurological Disorders and Stroke
(NINDS) in the US [13]. Surprisingly, levetiracetam was
ineffective in the standard MES and pentylenetetrazole
tests in rats and mice, up to doses of 500 mg/kg
intraperitoneally, but was highly effective in suppressing
partial and secondarily generalized convulsive seizures in
amygdala-kindled rats [12]. In contrast to the lack of effect
in the standard MES and pentylenetetrazole tests, leve-
tiracetam (27–108 mg/kg intraperitoneally) moderately
increased the thresholds for MES (MEST) and myoclonic
and clonic seizures induced by timed intravenous infusion
of pentylenetetrazole with maximum effects of approxi-
mately 30 % at the highest dose tested. In kindled rats,
levetiracetam increased the focal seizure threshold (after-
discharge threshold [ADT]) by 150 % at 54 mg/kg
intraperitoneally, demonstrating the particular efficacy of
levetiracetam in this model [12]. Figure 3 illustrates the
striking difference in levetiracetam’s efficacy to increase
the seizure threshold in amygdala kindled rats versus
MEST in non-kindled rats, suggesting that the chronic
brain alterations associated with kindling render leve-
tiracetam effective. At doses up to 1700 mg/kg
intraperitoneally, levetiracetam was inactive in tests
measuring ‘minimal neurological deficit’, i.e. the rotarod
and chimney tests, indicating a high therapeutic index
[12]. These findings revealed a unique profile that made
levetiracetam the first known ASD to display efficacy in
fully kindled rats, while showing absence of anti-seizure
activity in the two major screening models (MES,
pentylenetetrazole) used over several decades for identi-
fying new ASD candidates (Table 1). This was in sharp
contrast to the profile of numerous previously screened
ASDs in these models [10], and unexpected because focal
and secondarily generalized seizures in amygdala kindled
rats are typically more difficult to suppress by ASDs than
acute seizures in the MES test [14]. Based on these data,
Lo¨scher and Ho¨nack [12] proposed that levetiracetam
should be particularly effective against partial seizures,
which was later confirmed by clinical trials, thus vali-
dating the data from the kindling model [10]. In subse-
quent studies in the early 1990s, published by Lo¨scher
et al. in 1998 [15], it was shown that treatment of rats with
levetiracetam during amygdala kindling retards kindling
acquisition and that this effect outlasted the period of drug
treatment, indicating potential antiepileptogenic or dis-
ease-modifying activity, which was subsequently con-
firmed by other groups (see Sect. 6). This distinct profile
of levetiracetam prompted UCB Pharma to pursue leve-
tiracetam as an ASD candidate. Scientists at UCB con-
tinued to test levetiracetam in various animal models,
including acute, chronic, and genetic models of seizures
or epilepsy, and data from these experiments (Table 1)
further confirming a unique profile of levetiracetam con-
sisting of a broad spectrum of efficacy in animal models
of acquired and genetic epilepsy, in contrast with a lack of
anti-seizure activity in various models of acute seizure
induction in normal animals [16, 17]. Following numer-
ous clinical trials, levetiracetam was eventually approved
by the FDA in November 1999 and the EMA in
September 2000 as a novel ASD [10]. In subsequent
years, several clinical studies confirmed the efficacy and
safety of levetiracetam, and the drug became the most
prescribed newer generation ASD for the treatment of
epilepsy [18].





The unusual preclinical profile of levetiracetam indi-
cated that its antiepileptic properties likely involve a novel
mechanism not shared by other ASDs. Indeed, a vast
number of studies, conducted at therapeutically relevant
concentrations, did not show any direct interaction of
levetiracetam with mechanisms through which other ASDs
act, including inhibition of sodium and low-voltage acti-
vated calcium (T-type) channels [17]. However, some
cellular and molecular effects of levetiracetam have been
reported at therapeutically relevant concentrations,
including inhibition of high-voltage-gated (N-type) cal-
cium and AMPA currents, inhibition of calcium release
from intracellular stores, effects on the metabolism and
turnover of GABA in discrete brain regions, reduction in
the firing activity of GABAergic neurons in substantia
nigra pars reticulata in vivo, and reversal of zinc-induced
inhibition of GABAA receptors [5]. Although these effects
may contribute to the unique pharmacological profile of
levetiracetam, their modest magnitude suggested that they
do not represent the primary mechanism of action.
In 1993, pioneering studies at UCB Pharma led to the
identification of a specific binding site for [3H]-levetirac-
etam, which became known as the levetiracetam binding
site (LBS), preferentially localized on synaptic plasma
membranes with high prevalence in a number of brain
structures, including the hippocampus, cortex, and cere-
bellum [19]. Levetiracetam was found to bind saturably,
reversibly, and stereospecifically to LBS, unlike other
Fig. 3 Effect of LEV on the a MEST in non-kindled rats, and
b threshold for secondarily generalized seizures in amygdala-kindled
rats. c, d Effect of BRV and SEL on the GST in amygdala-kindled
rats. Data are shown as means ± SEM of a 20 non-kindled and b–d 9
fully kindled rats in percentage seizure threshold increase above
vehicle control seizure thresholds. Significant differences to control
thresholds are indicated by an asterisk (p\ 0.05). Note the marked
difference in anti-seizure efficacy of LEV in a non-kindled vs.
b kindled rats. All drugs also significantly increased the threshold for
focal seizures (ADT) in kindled rats. The minimum doses signifi-
cantly increasing ADT were 1.25 mg/kg (LEV), 0.68 mg/kg (BRV),
and 0.0074 mg/kg (SEL). Data on MEST in non-kindled rats are
taken from Lo¨scher and Ho¨nack [12], and data on kindled rats are
from Potschka and Lo¨scher (unpublished observations). LEV leve-
tiracetam, MEST maximal electroshock seizure threshold, GST
generalized seizure threshold, BRV brivaracetam, SEL seletracetam,
SEM standard error of the mean, ADT after-discharge threshold, i.p.
intraperitoneally
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tested ASDs or CNS drugs that lacked any significant
affinity to LBS. Further studies also demonstrated a strong
correlation between the affinity of a series of levetiracetam
analogs to the LBS, both in vitro and ex vivo, and their
anticonvulsant potency in the audiogenic seizure model
[19]. In 2003, the molecular nature of LBS was discovered
and identified as the synaptic vesicle glycoprotein 2A
(SV2A) [6]. Subsequently, the correlation between SV2A
binding affinity and anti-seizure potency was confirmed in
the audiogenic seizure model and extended to other models
of epilepsy (Fig. 4) [20]. Further supportive evidence for a
role of SV2A in the anti-seizure activity of levetiracetam
came from studies in heterozygous SV2A knockout (?/-)
mice. In these animals harboring a 50 % reduction in
SV2A proteins, levetiracetam displayed a reduced anti-
seizure activity compared with wild-type animals, while
valproate, not acting through SV2A, had equal efficacy in
both strains [21]. These findings provided further support
for SV2A being a valid and novel target for further ASD
discovery research and its role in epilepsy [9].
3 The Role of SV2A in Modulating Neuronal
Excitability in the Brain
Synaptic transmission is initiated when an action potential
triggers neurotransmitter release from presynaptic nerve
terminals by synaptic vesicle exocytosis. Traditionally,
synaptic vesicle exocytosis is divided into four sequential
stages (Fig. 5). First, neurotransmitters are transported into
synaptic vesicles, then vesicles dock at the active zone
(docking), and prime at the plasma membrane (priming or
preactivation). Finally, primed vesicles are triggered for
exocytosis by Ca2? [22–24]. Vesicle exocytosis is followed
by vesicle endocytosis and recycling (Fig. 5). SV2, one of
the first synaptic vesicle proteins identified, is a component
of all vertebrate synaptic vesicles [25]. Three SV2 isoforms
are known, two major (SV2A and SV2B) and one minor
isoform (SV2C). These proteins constitute a distinct pro-
tein family containing 12 transmembrane regions (Fig. 6a).
The expression of these SV2 isoforms has been mapped in
the central nervous system [26]. SV2A is the most
Table 1 Preclinical profile of LEV and BRV in rodent models of seizures (other anti-seizure drugs are shown for comparison). Data for
‘minimal neurological deficit’ (neurotoxicity) determined by the rotarod test are also shown
Model ED50 (mg/kg intraperitoneally)
LEV BRV SEL PHT CBZ LTG VPA
Screening models
MES test (mice) [540 113 [232 5.6 7.8 7.5 260
Subcutaneous PTZ test (mice) [540 30 [232 [50 [50 [50 220
6-Hz model (mice; 44 mA [=2 9 CC97]) 1089 4.4 ? [60 ? [60 310
Genetic models
Audiogenic seizures in DBA/2 mice 30 2.4 0.17 3.9 11 2.4 155
SWDs in GAERS (rats) 5.4 (MAD) 6.8 (MAD) 0.15 NE NE NE 81
Kindling models
Corneally kindled mice (secondarily generalized seizures) 7.3 1.2 0.31 67 9 37 110
Amygdala-kindled rats (ADT) 1.25 (MAD) 0.68 (MAD) 0.0074 (MAD) 30 [20 *10 (MAD) 300
Amygdala-kindled rats (GST) 1.25 (MAD) 0.68 (MAD) 0.0074 (MAD) 50 8 ? 190
Hippocampus-kindled rats (secondarily generalized seizures) 54 (MAD) 0.2 (MAD) 0.23 (MAD) [120 30 61 152
Minimal neurotoxicity (rotarod test)
Neurotoxicity in naive mice 2223 195 503 41 45 30 400
Neurotoxicity in naive rats 1960 *370 [743 140 33 411 (orally) 394
Neurotoxicity in corneally-kindled mice 1036 55 325 99 33 29 184
Neurotoxicity in amygdala-kindled rats 1119 163 520 ? 32 ? 300
Data taken from Lo¨scher et al. [14], Marescaux and Vergnes [154], Ebert et al. [155], Ho¨nack and Lo¨scher [156], Barton et al. [49], Bialer et al. [157],
Matagne and Klitgaard [158], Matagne et al. [108], Bennett et al. [130], Klitgaard et al. [9], Lo¨scher [159], Lo¨scher et al. [160], and unpublished
experiments
ADT after-discharge threshold, BRV brivaracetam, CBZ carbamazepine, CC97 current inducing seizures in 97 % of mice, ED50 median effective dose,
GAERS genetic absence epilepsy rat from Strasbourg, GST generalized seizure threshold, LEV levetiracetam, LTG lamotrigine,MADminimum active dose
providing significant protection against the seizure endpoint, MES maximal electroshock seizure, NE not effective, PHT phenytoin, PTZ pentylenete-
trazole, SEL seletracetam, SWDs spike-wave discharges, VPA valproate
? indicates no data are available
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abundant isoform, ubiquitously present throughout all brain
areas, with the exception of the trigeminal and facial nuclei
[27]. SV2A is expressed in excitatory and inhibitory
synapses, as observed in the hippocampus, cerebellum, and
cortex [27], and is particularly abundant in subcortical
areas, such as the thalamus and basal ganglia [28]. In
contrast to SV2A, SV2B has a more restricted expression
pattern; however, it is widely coexpressed with SV2A in
many, but not all, synaptic vesicles of nerve terminals,
including the hippocampal pyramidal cells [27, 28]. SV2C
displays an even more restricted pattern of expression,
which, under physiological conditions, is mainly limited to
basal ganglia and the brain stem [29, 30]. SV2A is the only
SV2 isoform expressed in many inhibitory, GABAergic
neurons [27, 31]. The human SV2A gene is located in the q
arm of chromosome 1 at locus 21.2; it is approximately
14.565 bp in size, and encodes a 4353 bp messenger RNA
(mRNA) with 13 exons, which is translated to an 82.6 kDa
protein composed of 742 amino acids (Fig. 6a) [26].
Although it is known that SV2A is involved in normal
synaptic vesicle function, its exact role is not fully under-
stood [26]. Among the various functions proposed are roles
in calcium-dependent exocytosis, neurotransmitter loading/
retention in synaptic vesicles, and synaptic vesicle priming,
as well as transport of vesicle constituents [5]. The latter is
supported by homology with the major facilitator super-
family (MFS) of membrane transport proteins [32] and by
the suggestion that SV2A is a galactose transporter [33].
Mice lacking SV2A generated by targeted gene disruption
[34] appear normal at birth, but do not grow normally; they
express seizures and die within 3 weeks, suggesting mul-
tiple neural alterations. Interestingly, hippocampal SV2A
expression increases in wild-type mice between postnatal
day (PND) 5 and 7, and remains stable from PND 7–10
[35]. The observed alterations of SV2A expression in
hippocampus are consistent with the appearance of seizures
in SV2A knockout animals at early postnatal age and the
hypothesis that SV2A absence favors epileptic seizures.
Electrophysiological studies of spontaneous inhibitory
transmission in the hippocampal CA3 region of these ani-
mals revealed that loss of SV2A induces a decrease in
action-potential-dependent GABA transmission, without
changes in action-potential-independent transmission.
Altered transmission in SV2A (-/-) animals was not
attributable to changes in the number or morphology of
synapses or SVs, indicating that SV2 proteins are not
structural components of synapses nor are they required for
SV biogenesis [34, 36]. These results support the hypoth-
esis that SV2A is a key player in the control of exocytosis,
and, consequently, has a key involvement in neurotrans-
mission [34]. The strong epilepsy phenotype of animals
with deletion of the SV2A gene, together with the fact that
SV2A binding is involved in the mechanism of action of
levetiracetam, has stimulated studies to further characterize
the potential role of SV2A in the epileptogenic process.
3.1 SV2A in Animal Models of Epilepsy
Gorter et al. [37] were the first to describe that SV2A gene
expression is transiently downregulated during epilepto-
genesis in the entorhinal cortex of rats in which epilepsy
was induced by sustained electrical stimulation of the
angular bundle. In a subsequent study, van Vliet et al. [38]
reported that SV2A protein expression was decreased in the
latent period of this model in the inner molecular layer and
stratum lucidum of the hippocampus. In chronic epileptic
Fig. 4 Correlation between the anti-seizure activity of a series of LEV
analogs in different epilepsy models and their SV2A in vitro binding
affinities. a Genetically sound-susceptible mice; b corneally kindled
mice; c rats with spontaneous absence-like EEG seizures from the
GAERS strain. SV2A binding affinities pIC50 (-logIC50) were measured
in rat brain membranes with the use of [3H]ucb 30889. Protective
potencies, based on dose-response studies, are shown as pED50 (-
logED50). All correlations were statistically significant (p\0.01). From
Kaminski et al. [20]. LEV levetiracetam, EEG electroencephalogram,
GAERS genetical absence epilepsy rats from Strasbourg, SV2A synaptic
vesicle protein 2A. ED50 median effective dose, IC50 half maximal
inhibitory concentration, pED50 logED50, pIC50 logIC50
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rats, SV2A was decreased throughout the hippocampus,
specifically in rats with a progressive form of epilepsy,
resembling the hippocampal SV2A decrease observed in
patients with TLE and hippocampal sclerosis [38].
In a systems level, functional genomics analysis of
chronic epilepsy using the intrahippocampal kainate model
of TLE in rats, Winden et al. [39] found that the network
structure and connectivity of the SV2A gene showed sig-
nificant changes between normal and epileptogenic dentate
gyrus, becoming more highly connected in epileptic brain,
possibly indicating that SV2A had gained a more important
role in synaptic function in epilepsy than under normal
conditions. The authors suggested that genes upregulated
due to seizures may regulate neuronal excitability through
effects on vesicular trafficking, and that SV2A represents a
central (hub) gene in this respect. This hypothesis would
contribute to an explanation of the unique pharmacological
profile of levetiracetam, which shows consistent efficacy in
Fig. 5 Schematic representation of the dynamics of SVs at the
presynaptic terminal, illustrating detailed mechanism of NT release
and synaptic vesicle recycling. SVs are specialized spheroidal membrane
structures that traffic along the axon to the presynaptic terminals, where
they internalize and store NTs (blue dots). The SV membrane harbors
proteins, some of them highly glycosylated (synapsin, synaptotagmin,
SV2, and synaptophysin), whose precise sorting is required for an
efficient neurotransmission. A magnified view of an SV (top left) shows
the main identified vesicular proteins (except for the proton pump).
Some SV proteins, such as synapsins or SV2s, come in multiple
isoforms. Once SVs are loaded by NTs, a number of processes lead to
excocytosis. (1) NT-loaded SVs dock to the presynaptic membrane by
interaction of Rab3 with the RIM protein. Docking displays the SVs in
close contact with the SNARE ternary complex (syntaxin 1, SNAP25,
and VAMP) and SNARE effectors (MUNCs). (2) Preactivation
(priming). In response to increased presynaptic concentrations of Ca2?,
sensed by synaptophysin, proteins of the complex change conformation,
inducing SVs to fuse with the plasma membrane and release their
contents into the synaptic cleft. (3) Fusion/release. Subsequently, empty
SVs undergo coating with clathrin polymers, and dynamin-driven
scission from plasma membrane. (4) Coating/scission allows SV
membrane proteins to be recycled. SV2s are thought to be involved in
several of these processes, including calcium-dependent exocytosis, NT
loading/retention in synaptic vesicles, and synaptic vesicle priming, as
well as transport of vesicle constituents. Updated and modified from
Rossetto et al. [23]. SVs synaptic vesicles, NT neurotransmitter, SV2
synaptic vesicle protein-2, Syt synaptotagmin, VAMP vesicle integral
membrane protein, SNARE soluble N-ethylmaleimide-sensitive factor
attachment protein receptor, RIM proteins a family of active zone
proteins, SNAP25 synaptosomal-associated protein 25, MUNC mam-
malian uncoordinated proteins, ADP adenosine diphosphate, ATP
adenosine triphosphate
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animal models of acquired and genetic epilepsy but lacks
an effect against acute seizure induction in normal animals.
In spontaneously epileptic rats (SERs), Hanaya et al.
[40] found low SV2A expression, particularly in the frontal
and entorhinal cortices and the inner molecular layer and
dentate gyrus of the hippocampal formation. SERs are
characterized by a double mutation (zi/zi, tm/tm) which
causes tonic convulsions, absence seizures, and sclerosis-
like changes in the hippocampus [40]. Levetiracetam
inhibits both tonic convulsions and absence seizures in
these rats, despite the low level of SV2A expression.
In apparent contrast to the reduced expression of SV2A
found in the hippocampus and other brain regions of two
rat models of TLE [38, 40], increased expression of SV2A
has been reported for the kindling model of TLE [41–44].
A likely, at least partial, reason for this discrepancy is the
massive neuronal loss in the hippocampus and parahip-
pocampal areas, occurring in post-status epilepticus (SE)
models of TLE (and many TLE patients), but not kindling.
When rats were kindled by repeated short (0.8 s) unilateral
stimulations of the amygdala, entorhinal cortex or septum,
the expression of synaptosomal SV2s (SV2A/SV2B) in the
ipsilateral hippocampus significantly increased, regardless
of the stimulation site [41]. The asymmetric accumulation
of SV2s that was observed 4 weeks after the last kindling
stimulation was specific to the hippocampus; it was not
seen at synaptically distant sites (occipital cortex and
cerebellum) that are not thought to be directly involved in
the neural network of kindling. In a subsequent study,
Matveeva et al. [42] reported that the ipsilateral accumu-
lation of SV2s in the hippocampus persists for at least
1 year and can be prevented by treating rats with leve-
tiracetam during kindling acquisition. In contrast, leve-
tiracetam had no effect on SV2 expression in non-kindled
rats.
An increase in hippocampal SV2A expression was also
observed in mice kindled by repeated administration of
pentylenetetrazole [43, 44]. Twenty-four hours after the
Fig. 6 Schematic
representation of SV2A.
a SV2A is comprised of 2 TM
domains (each of which is
comprised of 6 TM helices) and
three extramembranous
domains, namely the amino
domain (blue); a long
intervening loop spanning
region between TM helices 6
and 7 (orange); and an
extracellular domain between
TM helices 7 and 8 (green). 2D
protein topology
figure generated using Protter
[152]. Models of b inward-open
(based on GlpT template) and
c outward-open (based on FucP)
conformations of the SV2A
protein [86] aligned using the
numbering system for proteins
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last pentylenetetrazole injection, intense SV2A expression
was found in the hilus of the dentate gyrus, but not in other
regions, including the stratum lucidum of CA3 and the
synaptic layer surrounding CA1 and CA3 pyramidal cells
[44]. In addition, pentylenetetrazole kindling selectively
elevated SV2A expression in GABAergic interneurons
located in the hilus of the DG, but not in mossy gluta-
matergic fibers [44]. The authors postulate that increased
SV2A expression in the hippocampus of kindled rats is a
compensatory mechanism that facilitates inhibitory
GABAergic neurotransmission [43, 44].
SV2A-deficient mice exhibit increased kindling acqui-
sition, both when kindled via repeated electrical stimula-
tion of the amygdala or by corneal stimulation [21]. A
proepileptic phenotype of SV2A (?/-) heterozygous mice
was also observed in pilocarpine, kainate, pentylenetetrazol
and 6 Hz models, but not in the MES test [21]. This profile
matches the protective profile associated with the activity
of levetiracetam in these models (Table 1).
3.2 Potential Role of SV2A in Models
of Pharmacoresistant Epilepsy
In the early 1990s, Lo¨scher and Rundfeldt developed the
first animal model of pharmacoresistant seizures, i.e. the
phenytoin-resistant amygdala-kindled rat [45]. This model
was discovered by evaluating the anti-seizure effect of
phenytoin in large groups of kindled rats, resulting in three
subgroups—responders, non-responders, and variable
responders (cf, [46]). In phenytoin non-responders, even
large doses of phenytoin did not increase the threshold for
focal seizures (ADT), whereas ADT was significantly and
reproducibly increased in the responder subgroup. The lack
of anti-seizure response in non-responders extended to
various other ASDs, with the remarkable exception of the
SV2A ligand levetiracetam [47], which suggests that SV2A
could be involved in the response of phenytoin non-re-
sponders to levetiracetam. Wang et al. [48] selected
phenytoin- and phenobarbital-resistant rats from a large
group of amygdala-kindled rats and found that hippocam-
pal SV2A mRNA and protein expression were significantly
lower in resistant rats compared with ASD responders.
Hippocampal low-frequency stimulation increased SV2A
expression in the resistant rats and exerted anti-seizure
effects [48]. The authors suggest that decreased levels of
SV2A are involved in the mechanism underlying pharma-
coresistant epilepsy. This suggestion is supported by the
findings of decreased SV2A levels in different types of
pharmacoresistant epilepsy in patients (see Sect. 3.3).
The high efficacy of levetiracetam in models of phar-
macoresistant epilepsy was also supported by experiments
with the 6-Hz mouse model of difficult-to-treat partial
seizures [49]. Bankstahl et al. [50] applied this model in
mice that had been rendered epileptic by a pilocarpine-
induced SE, and observed that levetiracetam was much
more effective in blocking 6-Hz seizures in epileptic mice
rather than non-epileptic mice, which was substantiated by
Leclercq and Kaminski [51]. In SV2A-deficient mice, anti-
seizure efficacy of levetiracetam in the 6-Hz model was
significantly reduced (approximately 50 %), consistent
with reduced binding to SV2A in these mice [21]. In
contrast, valproate produced the same anti-seizure effect in
wild-type and SV2A-deficient mice. It is tempting to
speculate that the striking increase in the anti-seizure effect
of levetiracetam on 6-Hz seizures in epileptic mice is
mediated by epilepsy-associated changes of its target,
SV2A [50, 51]. Indeed, profound changes in synaptic
vesicle release machinery were reported in post-SE models
of TLE; however, SV2A density in individual synaptic
boutons has not been directly measured in these studies
[52, 53].
3.3 SV2A in Patients with Pharmacoresistant
Epilepsy
SV2A expression has been analyzed in patients experi-
encing different types of intractable epilepsy, owing to the
availability of brain tissue removed from these
patients during epilepsy surgery [26]. As in post-SE rat
models of TLE (see Sect. 3.1), SV2A expression was
reduced by 30–50 % in the anterior temporal neocortex of
adult patients with TLE [54]. Weak SV2A immunoreac-
tivity (IR) was observed in the tissue from TLE patients,
whereas strong IR was present in brain tissue from control
patients [54]. SV2A expression, measured by Western
blotting, was significantly decreased in the temporal neo-
cortex of TLE patients compared with control patients [54].
Likewise, SV2A expression was decreased in the resected
hippocampus of patients with TLE and hippocampal scle-
rosis [37]. A substantial loss of SV2A IR was observed in
the hippocampal neuropil, except in the inner molecular
layer of the dentate gyrus [37]. These observations were
recently further substantiated with positron emission
tomography (PET) studies, where decreased binding (ap-
proximately 50 %) of an SV2A tracer (11C-UCB-J) was
observed ipsilaterally to the seizure focus in patients with
TLE [55]. Malformations that cause intractable epilepsy,
such as focal cortical dysplasia and cortical tubers, also
show significantly reduced SV2A IR [56]. SV2A IR within
the dysplastic cortex had less staining than the normal
cortex. This decrease was also observed by Western blot
analysis in both the focal cortical dysplasia and the tuber-
ous sclerosis complex [56]. These results suggest that
decreased SV2A expression may contribute to the insta-
bility of neuronal networks and therefore to the progression
of epilepsy [54, 56]. Further work is needed to fully
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interpret those findings since immunohistological and PET
assessments of SV2A expression could be confounded by
neuronal loss often observed in TLE. It is essential to study
SV2A at the level of individual synapses in patients with
TLE since recent reports indicate significant increases in
synaptic vesicle density within limbic structures of animals
with chronic TLE [52, 53].
In addition, the expression and distribution of SV2A
have been investigated in patients with brain tumors with
or without epilepsy [57]. Strong and diffuse SV2A IR was
observed throughout all layers of the control cortex. Sim-
ilarly, strong SV2A IR (with the same diffuse distribution
pattern) was observed in peritumoral cortical specimens
from patients with and without epilepsy. Modest SV2A IR
was observed within the tumor area [57]. Although the
mechanisms of SV2A function are not fully understood, a
reduction in SV2A expression appears to lead to abnormal
neurotransmission and the development of seizures
[34, 36]. However, as SV2A expression in the peritumoral
tissue was similar in patients with or without epilepsy
(although tumor cells of patients with and without epilepsy
showed modest SV2A IR and lower SV2A protein
expression than the control cortex), the role of SV2A in
epileptogenesis in tumor patients remains questionable
[57]. Alternatively, the reduced SV2A expression and
subsequent loss of SV2A function may lead to dysfunction
of SV exocytosis and to altered neurotransmission, con-
tributing to epileptogenesis in patients with brain tumors
[57]. In a subsequent prospective study, de Groot et al. [58]
found that SV2A expression in tumor and peritumoral
tissue correlated with the efficacy of levetiracetam in post-
surgical patients, suggesting an association between SV2A
expression and levetiracetam response, an association that
has been previously observed [21].
Recently, the first evidence that an SV2A mutation can
cause epilepsy in humans was reported [59]. These inves-
tigators found an homozygous mutation in the SV2A gene
in a patient with intractable epilepsy. Exome sequencing
identified a homozygous arginine to glutamine mutation in
amino acid position 383 (R383Q) in exon 5 of the SV2A
gene. Both parents were carriers for the R383Q variant,
suggesting that R383Q is a recessive mutation. There were
no other candidate alterations in the exome that could
explain the phenotype in the patient.
3.4 SV2A in Cognitive Impairment
Elevated hippocampal excitability is observed in a number
of conditions that confer risk for Alzheimer’s disease (AD),
including amnestic mild cognitive impairment (aMCI)
[60]. By using treatment with a low dose of levetiracetam
(125 mg twice daily), hippocampal activation in patients
with aMCI was reduced to a level that did not differ from
the control group, and memory performance was signifi-
cantly improved [60], substantiating previous experiments
with levetiracetam in a rat model of age-related memory
loss [61]. By using differential coexpression analysis
(DCA) to disentangle causative events from secondary
changes within transcriptome-wide gene expression data
sets, SV2A has been identified as a causal ‘node’ or ‘master
regulator’ in late-onset AD, involved in modulation of
amyloid b/A4 precursor protein (APP) processing [62]. In
in vitro experiments in cells cultured from carriers of
apolipoprotein E (APOE)-4, which is the greatest genetic
risk factor for late-onset AD, treatment with the SV2A
ligand levetiracetam could correct APOE4-related alter-
ation in APP processing [62]. Levetiracetam treatment of
APP transgenic mice has similarly been reported to
improve cognitive function, whereas other anti-seizure
agents fail to do so [63]. In a cell model for aging and early
late-onset AD, levetiracetam improved several aspects of
mitochondrial dysfunction, which were abolished when
SV2A was knocked down by small interfering RNA
(siRNA), indicating that interfering with SV2A at the
mitochondrial level, and thereby improving mitochondrial
function, might represent an additional therapeutic effect of
levetiracetam to improve symptoms of late-onset AD [64].
Taken together, these data support a potential role of SV2A
in AD and have stimulated an interest in exploring the
therapeutic potential of levetiracetam as a novel thera-
peutic approach for AD treatment.
In a prospective, randomized, case-control study of AD
patients with seizures, treatment with either levetiracetam,
phenobarbital, or lamotrigine exhibited the same efficacy
to suppress seizures, but, in addition, treatment with leve-
tiracetam was associated with improved cognitive perfor-
mance, specifically improved attention, short-term
memory, and oral fluency, while this was not seen with
phenobarbital or lamotrigine [65]. Instead, patients
receiving phenobarbital showed a significant worsening of
cognitive performance and patients treated with lamotrig-
ine showed a slight decline in cognitive function [65].
Currently, several phase II and III studies with levetirac-
etam in AD patients are being performed (see
ClinicialTrials.gov).
Several high-affinity SV2A ligands were recently dis-
covered that are devoid of anti-seizure activity and selec-
tively counteract the anti-seizure effect of levetiracetam,
but not that of other ASDs [66]. Due to their opposite
action to levetiracetam, UCB scientists speculated that this
finding may reflect similarity to other receptors (GABA
and AMPA) and ion channel (KCNQ2/3) systems where
pharmacological modulation opposite to the one providing
anti-seizure effects elevates neuronal excitability and
results in procognitive effects. This was confirmed when
testing several SV2A ligands, devoid of anti-seizure
1064 W. Lo¨scher et al.
properties, in the object recognition test in mice. Among
these, UCB0255 was selected as a lead candidate. It dis-
plays high selectivity and affinity (pKi = 7.9) for SV2A
and reveals a pharmacology for SV2A opposite that of
levetiracetam by an absence of anti-seizure properties and
an ability to counteract the seizure protection afforded by
levetiracetam [66]. Further characterization of UCB0255 in
various animal models of cognition substantiated the
procognitive hypothesis of this class of SV2A ligands [66].
The finding that both an anticonvulsant SV2A ligand
(levetiracetam) and a SV2A ligand devoid of anticonvulsant
properties (UCB0255) exert procognitive activity indicates
that these compounds interact differently, depending on the
circumstances. The procognitive effect of levetiracetam may
be observed in conditions where there is background
hyperexcitability (e.g. MCI), while SV2A ligands devoid of
anticonvulsant effects may exert their procognitive activity
by enhancement of neuronal excitability in advanced AD
associated with hypoexcitability (e.g. analogous to cholin-
ergic drugs). Clearly, what the underlying cause of the
cognitive deficit is, i.e. hyper- or hypoexcitability needs to
be carefully assessed before treatment with either type of
SV2A ligand is considered.
3.5 Role of SV2B and SV2C Isoforms
Little is known about physiological functions of SV2B and
SV2C isoforms beyond observations indicating different
expression patterns in the brain, or association with par-
ticular types of either excitatory or inhibitory neurons. It
appears that SV2B levels are very low in the synaptic
vesicles of GABAergic neurons compared with SV2A, and
appear to have a preferential localization in glutamatergic
neurons [67]. However, the functional consequence of this
finding may be limited, at least under physiological con-
ditions, since SV2B knockout mice lack any overt pheno-
type [68]. Furthermore, both the frequency and amplitude
of spontaneous excitatory and inhibitory postsynaptic cur-
rents is not significantly altered in SV2B knockout mice
[69]. The role of SV2B may become more apparent under
disease conditions since SV2B knockout are protected
against Ab25–35-induced oxidative stress and decrease in
choline acetyltransferase activity in the hippocampus [68].
Furthermore, SV2B knockout mice failed to show
Ab25–35-induced impairments in a range of cognitive
domains [68]. The SV2B knockout mice, unlike SV2A-
deficient mice, have only a limited phenotype in seizure
models and show a slight decrease in vulnerability to 6 Hz-
, pilocarpine- and kainate-induced seizures and reduced
pentylenetetrazole seizure threshold (Leclercq and
Kaminski, unpublished observations).
Similar to SV2B knockout mice, the SV2C-deficient
animals also do not display any overt phenotype under
physiological conditions, but changes in SV2C expression
have been reported in tissue from disease models and
patients. Cre`vecoeur et al. [70] studied the expression
pattern of all three isoforms of SV2 in the hippocampus of
patients with TLE and hippocampal sclerosis. They found
that the expression of SV2 isoforms is altered with a
marked decrease of SV2A and SV2B paralleling synaptic
loss and a selective increase of SV2C in sprouting mossy
fibers. Similar findings were made in mice with TLE
resulting from electrical stimulation of basolateral amyg-
dala followed by self-sustained SE, where selective SV2C
overexpression was seen in the CA4 and CA3 hippocampal
(stratum lucidum) areas [71]. Interestingly, SV2C mRNA
expression was also significantly increased in the striatum
of animals challenged with 6-hydroxydopamine, a model
of Parkinson’s disease [72]. Together, these data indicate
that SV2C may be involved in presynaptic remodeling in
response to neuronal hyperexcitability or cellular stress
conditions.
3.6 Investigation of SV2A by Positron Emission
Tomography Tracers
A highly selective SV2A radiotracer for brain imaging by
PET could help to further understand the physiological role
of SV2A and to reveal its fundamental implication in
various neurological diseases, characterized by a synaptic
dysfunction such as epilepsy or by a synaptic deconnection
such as in AD. Recently, [18F]UCB-H, a high-affinity PET
ligand for SV2A, was developed [73, 74]. This tracer
shows a nanomolar affinity for SV2A in the brain, which
has been demonstrated using lPET in a preclinical study
by Warnock et al. [75] in the rat brain. After a single
intravenous administration in rats, [18F]UCB-H showed
rapid and high-level brain uptake, with a free brain-to-
plasma ratio of greater than 1 at 5, 10, and 20 min after
administration. The uptake of [18F]UCB-H in the brain
corresponded to the reported distribution of SV2A, with
widespread tracer uptake in the entire brain. The first
human dosimetry study of [18F]UCB-H [76] showed that
the highest number of disintegrations per organ occurred in
the liver, followed by the bladder and the brain. Other PET
tracers based on 11C-labeling have been also recently
developed in preclinical species, e.g. [11C]UCB-A [77] and
[11C]UCB-J [78]. As with UCB-H, UCB-J [(R)-1-((3-
(methyl-11C)pyridin-4-yl)methyl)-4-(3,4,5-trifluo-
rophenyl)pyrrolidin-2-one] is a heterocyclic non-acetamide
compound [74]. Its whole body biodistribution was studied
in non-human primates, demonstrating high uptake and fast
kinetics in the brain [78]. Preblocking with levetiracetam
10 and 30 mg/kg resulted in approximately 60 and 90 %
occupancy, respectively. The recent evaluation demon-
strated that [11C]-UCB-J has exceptional imaging qualities
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for PET measurements of SV2A in the human brain,
including high brain uptake, rapid kinetics appropriate for
the 11C radiolabel, a high and reliably measurable free
fraction in plasma, and suitable regional time–activity
curves [78]. [11C]UCB-J displays rapid metabolism in
human subjects and excellent brain uptake, which is
highest in the striatum and the cortex, while being mod-
erate in the cerebellum and the thalamus (Fig. 7a) [55].
Interestingly, evaluation of a patient with TLE indicated a
significant reduction of [11C]UCB-J binding in the right
mesial temporal lobe colocalized with mesial temporal lobe
sclerosis seen on MRI (Fig. 7b) [55].
In addition to their potential value in the study of epi-
lepsy, SV2A PET tracers could be of interest as useful tools
to measure synaptic density in humans [55, 75]. SV2A does
not appear to affect vesicle formation as synaptic
Fig. 7 Characterization of a
novel SV2A PET radiotracer
[11C]UCB-J in humans. a Axial,
coronal and sagittal brain MRI
images in a healthy volunteer
subject (top row); regional
volume of distribution maps
(VT) during test (middle row)
and retest (bottom row) PET
scanning with [11C]UCB-J in
the same subject. b Axial and
coronal brain MRI images in a
patient with temporal lobe
epilepsy (top row); standardized
uptake value maps (SUV) of
[11C]UCB-J in the same subject
(bottom row). Arrows show
unilateral mesial temporal
sclerosis (MTS) seen on MRI
(top row) and reduced
radioligand binding in the
corresponding areas of the right
mesial temporal lobe of the
same subject (bottom row).





standardized uptake value, MTS
mesial temporal sclerosis, VT
volume of distribution
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morphology and vesicle density were not altered in SV2A
knockout animals [34, 36]. These data suggested that
SV2A could influence SV cycling. As this cycling is a
continuous process within the presynaptic terminal, it could
be postulated that reduced uptake of an SV2A PET tracer is
a consequence of synaptic loss [75], which clearly appears
to be the case in patients with mesial TLE [55]. Such a non-
invasive measure of synaptic density could be of great
value, not only for the diagnosis of epilepsy but also other
neurodegenerative disorders, including AD. In addition to
UCB-H and UCB-J, levetiracetam itself has been 11C-la-
beled and used as a PET tracer [79], but no imaging data
with this radiotracer have been reported to date.
4 SV2A as a Target for Anti-Seizure Drugs:
Levetiracetam, Brivaracetam and Beyond
As discussed above, there are different lines of evidence to
suggest that modulation of SV2A constitutes the primary
mechanism of action of levetiracetam [7, 80], although
other effects may contribute to its pharmacodynamic
activities. In a critical review on the role of SV2A for the
effects of levetiracetam, Surges et al. [81] concluded in 2008
that ‘‘although levetiracetam shares some targets with other
ASDs, levetiracetam exhibits unique mechanisms of action
and a novel and unique binding site’’. However, the latter
authors also noted that ‘‘unfortunately to date, there are no
available reports on the specific binding site for levetirac-
etam on the SV2A molecule’’. Respective studies are com-
plicated by the fact that SV2A has not been structurally
characterized with X-ray crystallography or nuclear mag-
netic resonance. By sequence homology, SV2A has been
described as a member of the Major Facilitator Superfamily
(MFS) of transporters [32, 82, 83] and is considered to adopt
the architecture found in the X-ray crystallography of the
MFS transporter family. Structural evidence for this even-
tually came from protein tomography experiments [84].
Using this technique, two major conformations could be
inferred. Although the sequence identity between SV2A and
other MFS proteins is very low, typically\20 %, homology
models have been constructed using available MFS x-ray
structures as templates. In an early study Shi et al. [85]
selected three residues—F658, G659 and V661—based on
their alignment with functionally relevant residues in LacY
for site-directed mutagenesis (SDM) studies with leve-
tiracetam and structurally-related analogs such as ucb
30889, collectively referred to as racetams, to elucidate
residues that are important for racetam binding. Further-
more, Shi et al. [85] constructed an SV2A homology model
using the LacY crystal structure as a template, and in con-
junction with racetam docking studies they proposed addi-
tional residues for SDM studies. In total, through binding
affinity experiments, 14mutants were found to be implicated
in racetam binding (F277A, W300A, W300F, Y462A,
K694A, G303A, F658A, V661A, I663A, W666A, N667A,
S294A, M301A, G659A) and were proposed to encompass
the SV2A racetam binding site. This work was extended in
the study of Lee et al. [86], wherein they considered two
conformational states based on two additional templates:
L-fucose-proton symporter as a template for the outward-
open state, and Glycerol-3-phosphate transporter as a tem-
plate for the inward-open state (Figs. 6b, c). On the basis of
the homology modeling, docking and subsequent molecular
dynamics simulations, these researchers observed that two
additional residues—W454 and D670—may contribute to
racetam binding. These predictions were subsequently borne
out by SDM performed on W454A and D670A in con-
junction with binding affinity assays [86]. Taken together
with the studies of Shi et al. [85], the outward-open con-
formation of SV2A (i.e. with the putative binding site
exposed to the interior of the synaptic vesicle) presents a
levetiracetam-binding pocket that is in greater agreement
with the SDM experiments.
In the former studies, only the transmembrane regions of
SV2A were modeled, which was a consequence of the fact
that a complete MFS protein structure has yet to be solved.
Recently, Correa-Basurto et al. [87] built a complete model
of the SV2A protein with levetiracetam, along with other
racetams (brivaracetam and seletracetam) docked into it.
The subsequent complexes were then simulated using
molecular dynamics in an attempt to further characterize
SV2A–racetam binding site interactions. Despite the short
timescale simulations and the challenge and caveats of
modeling the extramembranous domains, the studies sup-
port the putative binding pocket observed by Shi et al. [85]
and Lee et al. [86], and, furthermore, identified additional
hydrophobic and hydrogen bond interactions with T456,
S665 and L689, which may be important for ligand
recognition within the putative racetam binding site.
Studies with an SV2A positive allosteric modulator
(UCB1244283) indicated that the SV2A protein contains
multiple interacting binding sites that are linked via the
conformation of the protein [88]. One of the functional
consequences of levetiracetam binding to the SV2A protein
in brain slices was found to be a reduction in exocytosis
[89]. In hippocampal slices from non-epileptic rats, treat-
ment with levetiracetam reduces neurotransmission in
response to fast stimulus trains [89], consistent with the
drug blocking the effects of SV2 on vesicle priming. Fur-
ther studies showed that levetiracetam decreased vesicular
release in a dose-, time-, and stimulation-dependent man-
ner, suggesting that repetitive stimulation is required to
allow levetiracetam entry into recycling synaptic vesicles
and intravesicular levetiracetam binding to SV2A [90].
Most interestingly, the latency of drug action is much
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shorter when neurons are stimulated [91], suggesting that
levetiracetam preferentially targets hyperactive synapses.
Based on the experiments of Meehan et al. [91] in hip-
pocampal slices, Mendoza-Torreblanca et al. [26] sug-
gested that levetiracetam enters synaptic vesicles during
recycling and endocytosis (see Fig. 5) and escapes during
synaptic vesicle fusion, and that the site of binding between
levetiracetam and SV2A is an intravesicular portion of the
protein or a protein portion that can be accessed from the
intravesicular side. However, given the pharmacokinetic
properties of levetiracetam (and brivaracetam) [see
Sect. 5], one would expect these compounds to reach their
target through diffusion of membranes. The lag time
observed for the compounds to act might be related to
diffusion rate into tissues or slices, but additional studies
are needed to address the location and relevance of the
position of the SV2A binding site(s).
By studying the effects of overexpressing SV2A in
hippocampal neurons cultured to form autaptic synapses,
Nowack et al. [92] found that elevated expression of SV2
resulted in a neurotransmission phenotype that resembled
that seen in neurons from SV2 knockout mice, suggesting
that too much SV2 is as detrimental to neuronal function as
too little. Levetiracetam reversed the effects of excess
SV2A, suggesting that levetiracetam may modulate SV2
protein interactions. Furthermore, levetiracetam was shown
to accelerate the induction of supply rate depression at
excitatory synapses during incipient epileptic activity, an
effect that was absent in SV2A-deficient mice [93]. While
the underlying mechanistic effect of ligand binding is not
fully elucidated, one hypothesis could be that ligand
binding to SV2A would stabilize a certain conformation of
the protein, resulting in potentiation or optimization of its
function, and thereby providing seizure protection [88].
Brivaracetam displays a 15- to 30-fold higher affinity to
SV2A than levetiracetam and is selective for SV2A [8, 9].
Rat hippocampal slice studies comparing brivaracetam and
levetiracetam using high-frequency neuronal stimulation,
indicated that brivaracetam augments synaptic depression
and thereby decreases synaptic transmission at 100-fold
lower concentrations than levetiracetam [94]. In studies
with dye-loaded vesicles, brivaracetam slowed stimulation-
induced destaining (i.e. slowed vesicle release) signifi-
cantly more than levetiracetam [94], indicating that bri-
varacetam reduces vesicle mobilization more effectively
than levetiracetam, which may explain their distinct phar-
macodynamic properties (see Sect. 5).
Additionally, different binding properties for levetirac-
etam and brivaracetam to the SV2A protein might also
contribute to different pharmacological efficacies. These
were revealed by further studies with the SV2A allosteric
modulator UCB1244283 on human recombinant SV2A
expressed in HEK293 cells, and in human cortex [88, 95].
In cells expressing human SV2A, [3H]brivaracetam labeled
twice as many sites than [3H]levetiracetam. Moreover, co-
incubation of [3H]levetiracetam with the allosteric modu-
lator produced a modest increase in affinity for SV2A, but a
doubling in maximum binding capacity. In contrast, co-
incubation with the allosteric modulator increased the
affinity of [3H]brivaracetam to a much greater degree
(tenfold), while the increase observed in maximum binding
capacity was more modest (1.3-fold). Taken together, these
data suggest that levetiracetam and brivaracetam recog-
nize, induce, or stabilize different conformations of the
SV2A protein, which may provide the molecular rationale
for their distinct pharmacodynamic properties.
The accumulated experience from drug discovery efforts
for new anti-seizure SV2A ligands has revealed a diversity
in anti-seizure profiles that not only appears to correlate
with differences in affinity but also with different binding
properties for SV2A. Taken together with the recent
identification of high affinity SV2A ligands, devoid of anti-
seizure properties, and an allosteric modulator, this pro-
vides a diverse armamentarium of SV2A ligands able to
both activate, antagonize, and modulate the function of
SV2A. Hopefully, this will facilitate further understanding
of the function and therapeutic potential of SV2A as a
target for CNS drugs.
5 Preclinical and Clinical Profile of Levetiracetam
and its Congeners
Based on the unique preclinical pharmacology and mech-
anism of action of levetiracetam as a novel ASD, a major
drug discovery program was triggered at UCB with the
purpose of optimizing the therapeutic benefit of discovery
of the SV2A mechanism. The goal was to identify selec-
tive, high-affinity SV2A ligands possessing anti-seizure
properties superior to levetiracetam [96]. Approximately
12,000 compounds were screened in vitro for SV2A
binding affinity; 1200 were further screened in vivo for
seizure protection in audiogenic seizure-susceptible mice,
and approximately 30 compounds were selected and
broadly characterized in a variety of animal models of
seizures and epilepsy [9]. This led to the identification of
two distinct anti-seizure racetam families, both with high
affinity for SV2A but with different pharmacological
properties, which were named after their lead com-
pounds—brivaracetam and seletracetam (Fig. 2). In vitro
models of epilepsy showed that, while both brivaracetam
and seletracetam inhibited epileptiform hypersynchroniza-
tion, brivaracetam demonstrated a more pronounced ability
to inhibit neuronal hyperexcitability than seletracetam [9].
This likely explains brivaracetam’s seizure protection in
the MES and subcutaneous pentylenetetrazole tests
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(Table 1), albeit at relatively high doses, and its significant
protection against the partial seizure phase in animal
models of partial epilepsy [97]. Brivaracetam also differs
from levetiracetam by its selective, high affinity and dif-
ferential interaction with SV2A [9]. This likely explains its
superior ability to inhibit neurotransmitter release and more
potent and complete seizure suppression than levetiracetam
in animal models of partial, generalized, and drug-resistant
seizures (Table 1), a profile that triggered the decision to
focus on brivaracetam for further clinical development.
Interestingly, initial preclinical studies have also revealed
brivaracetam to possess a more significant antiepilepto-
genic potential than levetiracetam (see Sect. 6).
Brivaracetam displays a faster onset of anti-seizure
action in preclinical models than levetiracetam [9, 98],
which is likely due to levetiracetam having a relatively low
lipophilicity (LogD -0.64) contrasting a higher
lipophilicity of brivaracetam (LogD 1.04), leading to a
higher brain–blood barrier permeability of brivaracetam
[98]. As a consequence, displacement experiments in rhe-
sus monkey with the SV2A PET tracer [11C]UCB-J fol-
lowing single intravenous administration of brivaracetam
(5 mg/kg) and levetiracetam (30 mg/kg) showed that
plasma levels comparable to those following intravenous
administration of brivaracetam 100 mg and levetiracetam
1500 mg in epilepsy patients provided a faster displace-
ment of [11C]UCB-J by brivaracetam than levetiracetam
[98]. A sevenfold difference was observed in brain entry
speed, with brivaracetam having a predicted drug entry
half-time of only 3 min, whereas this figure was 23 min for
levetiracetam [98]. Together with high solubility and tol-
erability, and low risk of drug–drug interactions, the faster
SV2A occupancy by brivaracetam than levetiracetam
supports a promising potential of brivaracetam for the
treatment of acute seizures, including SE. The latter is also
reinforced by significant activity of brivaracetam in animal
models of SE [98].
An initial report suggested that inhibition of voltage-
gated sodium channels at low micromolar concentrations
may contribute to the anti-seizure activity of brivaracetam
[99]. However, several subsequent studies suggested that
the anti-seizure mechanism of brivaracetam is unrelated to
inhibition of voltage-gated sodium channels [9]. Further
studies on other potential ASD mechanisms, including
voltage-gated potassium channels, high- and low-voltage-
gated calcium channels, and GABA and glutamate cur-
rents, have shown no effect of brivaracetam at therapeuti-
cally relevant concentrations, suggesting that brivaracetam
represents the first, selective SV2A ligand for epilepsy
treatment [9].
The increased affinity for SV2A of brivaracetam over
levetiracetam shown in vitro correlates well with observa-
tions from various in vivo models of seizures and epilepsy
(Table 1) that show brivaracetam to have a markedly higher
potency over levetiracetam for protection of both general-
ized and partial seizures [8, 80, 100]. An example for dose–
effect comparisons between levetiracetam and brivaracetam
in amygdala-kindled rats is shown in Fig. 3. Furthermore, in
contrast to levetiracetam, brivaracetam is also effective
against seizures induced in the classical MES and
pentylenetetrazole seizure tests, albeit at relatively high
doses (Table 1). A particularly remarkable difference in
potency is seen in the 6-Hz model of pharmacoresistant
partial seizures. In this model, use of a high stimulation
current (44 mA) results in resistance of induced seizures to
many ASDs [49]. Anti-seizure ED50 of levetiracetam is
1089 mg/kg, whereas brivaracetam suppresses seizures with
an ED50 of 4.4 mg/kg (Table 1), indicating a 250-fold higher
anti-seizure potency in this model [101].
Pharmacologic studies have shown that brivaracetam, in
contrast to levetiracetam, exhibits significant activity in
animal models beyond epilepsy, which likely reflects the
improved ability of its selective SV2A mechanism to
inhibit synaptic transmission and vesicle release. These
preclinical findings suggest potential activity of brivarac-
etam in neuropathic pain, migraine, and tremor [9]. The
latter seems of particular interest as case reports [102] and
open-label observations [103] have suggested potential
anti-tremor activity of levetiracetam in some tremor types,
although this has not been confirmed by double-blind,
placebo controlled trials [104–107]. A determination of the
ratio between doses inducing adverse effects on motor
function in the rotarod test and seizure suppression, i.e. the
therapeutic index, which may be lower in epileptic than
non-epileptic individuals [3], showed brivaracetam to have
a lower therapeutic index in corneal-kindled mice than
levetiracetam (46 vs. 148, respectively); however, it was
markedly higher than that observed for classical and other
newer ASDs (therapeutic indexes 2–21) [9]. In contrast,
rotarod testing in amygdala-kindled rats showed brivarac-
etam to have a higher therapeutic index than levetiracetam
(4 vs. 2, respectively) [108].
Clinical studies have shown that levetiracetam is gen-
erally well tolerated [109]. The most common adverse
effects in epilepsy patients are somnolence, asthenia, and
dizziness, which usually appear early after initiation of
therapy and generally resolve without medication with-
drawal. The most serious adverse effects of levetiracetam
are behavioral in nature and are more common in children
and in adult epilepsy patients with a prior history of
behavioral problems and psychiatric disease [110]. The
more selective SV2A mechanism of brivaracetam versus
levetiracetam triggered UCB to perform a small, open-la-
bel study to assess if brivaracetam may be associated with
fewer behavioral adverse effects [111]. This study showed
that epilepsy patients experiencing behavioral adverse
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effects associated with levetiracetam benefited from
switching to brivaracetam. The good tolerability of bri-
varacetam was also seen in several larger clinical epilepsy
trials [112–116].
Several randomized, double-blind, placebo-controlled
studies in idiopathic generalized epilepsies have shown a
significant response of myoclonic seizures to levetiracetam
treatment, and the drug is approved by the EMA and FDA as
add-on treatment of juvenile myoclonic epilepsy [117, 118].
Levetiracetam is also frequently proposed as a treatment
opportunity for various types of myoclonus [119], and open-
label trial data even suggested potential antimyoclonic
effects in patients with Unverricht–Lundborg disease
[120, 121]. However, two phase III studies evaluating the
efficacy and safety of adjunctive therapy with brivaracetam
in these patients did not demonstrate a statistically significant
symptomatic relief of action myoclonus [122].
Brivaracetam has been clinically evaluated as adjunctive
therapy for adults with refractory partial-onset seizures. It
has demonstrated significant efficacy and good tolerability
in both phase II and III clinical studies [123, 124] and has
recently been approved by the EMA and FDA for this
indication. While brivaracetam and levetiracetam demon-
strated similar clinical efficacy, indirect comparisons using
available trials remain problematic due to the lack of
homogeneity between patient populations and other con-
founders (e.g. increasing refractoriness, increasing placebo
response rates over time) [125]. Interestingly, a post hoc
analysis of trial data from a recent major clinical study with
brivaracetam [116] on the impact of levetiracetam expo-
sure suggests seizure reduction in patients never exposed to
levetiracetam as well as those previously exposed to
levetiracetam, although the effect appeared to be greater in
the levetiracetam-naı¨ve population. The results of the
exploratory post hoc subgroup analysis by levetiracetam
exposure showed that statistically significant (p\ 0.05 vs.
placebo) seizure reduction occurred in both previously
levetiracetam-exposed and levetiracetam-naive patients.
Percentage reductions in seizure frequency over placebo
per 28 days and the C50 % responder rates were higher
across treatment groups for levetiracetam-naive patients
than for levetiracetam-exposed patients. However, it is
important to note that there was a response in patients with
previous levetiracetam exposure. This finding suggests the
possibility that brivaracetam may be an effective ASD in
some patients who have previously not responded to
levetiracetam, although these post hoc findings would need
to be confirmed in further clinical trials. In additional post
hoc analyses, greater efficacy was seen in the levetirac-
etam-naive group than in the prior levetiracetam group, and
this tendency was also seen with other ASDs (e.g. carba-
mazepine-, lamotrigine-, and topiramate-naive groups
compared with their prior-exposed counterparts) [126].
These findings support previous reports that suggest
patients who did not respond to previous ASDs are more
likely to demonstrate pharmacoresistance to additional
ASD treatment regimens [127, 128].
A review of the pharmacokinetic properties of brivarac-
etam in humans [101] has shown it to be well absorbed from
the gastrointestinal tract and to show linear pharmacokinet-
ics following single oral doses of up to 600 mg. The com-
pound is weakly bound to plasma proteins (B20 %) and its
volume of distribution is close to that of total body water
(0.6 L/kg). The terminal half- life of brivaracetam is
approximately 8 h and does not varywith dose [101]. Similar
to brivaracetam, a review of levetiracetam [129] has shown
linear and time-independent pharmacokinetics, with low
intra- and intersubject variability. The drug is rapidly and
almost completely absorbed after oral administration, and its
bioavailability is not affected by food. Levetiracetam has
low plasma protein binding and its volume of distribution is
close to the volume of total body water. Its plasma half-life
across studies is approximately 6–8 h but the clinical dura-
tion of action can last up to 30 h after a single dose, an
observation that led to use of a twice-daily dosing regimen in
clinical trials [129].
Seletracetam is the lead compound of the second anti-
seizure family, identified during the discovery program at
UCB focused on identifying selective and high affinity
SV2A ligands with anti-seizure properties superior to
levetiracetam (Fig. 2). Seletracetam was chosen from a
large group of SV2A ligands based not only on its higher
affinity for this target (tenfold greater affinity for SV2A
than levetiracetam) but also on its potency and efficacy, as
observed in in vivo and in vitro testing [130]. As shown in
Table 1 and Fig. 3, seletracetam is much more potent than
levetiracetam or brivaracetam in the amygdala kindling
model, but, in contrast to brivaracetam, ineffective in the
MES and pentylenetetrazole tests, thus demonstrating that
the two families of anti-seizure SV2A ligands markedly
differ in their pharmacology. Seletracetam shows very
potent seizure suppression in models of acquired or genetic
epilepsy, as well as high CNS tolerability in various animal
models [130, 131]. As with brivaracetam, seletracetam is
more selective for SV2A than levetiracetam [130]. In
clinical phase I studies, seletracetam was rapidly absorbed,
volume of distribution was approximately 0.6 L/kg, and
plasma terminal half-life was approximately 8 h in young
healthy male subjects [131].
6 SV2A Ligands for the Prevention of Epilepsy?
A major goal of contemporary epilepsy research is the
identification of therapies to prevent the development of
recurrent seizures in individuals at risk, including those
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with brain injuries, infections, tumors, febrile and afebrile
SE, cortical dysplasias, or genetic epilepsy susceptibility
[132]. The first indication that levetiracetam may exert not
only anti-seizure activity but also antiepileptogenic or
disease-modifying activity came from the study by Lo¨scher
et al. [15] in the amygdala-kindling model. When rats were
treated with levetiracetam during kindling acquisition at
daily intraperitoneal doses of 13, 27, or 54 mg/kg, the drug
dose-dependently suppressed the increase in seizure
severity and duration induced by repeated amygdala stim-
ulation. After termination of daily treatment with 54 mg/
kg, duration of behavioral seizures and after-discharges
recorded from the amygdala remained significantly shorter
compared with vehicle controls, although amygdala stim-
ulations were continued in the absence of drug. Therefore,
these data indicated that levetiracetam did not simply mask
the expression of kindled seizures through an anti-seizure
effect but exerted a true disease-modifying effect [15]. The
only other ASD, for which a similar effect had been
described previously, was high-dose treatment with val-
proate [133], whereas other ASDs just retarded kindling by
their suppressive effect on kindled seizures [134]. The
initial observation of Lo¨scher et al. with levetiracetam in
the amygdala-kindling model [15] was subsequently con-
firmed by Stratton et al. [135], who found that levetirac-
etam, but not lamotrigine (which was used as a
comparator), delayed or prevented the expected increase in
after-discharge duration during further kindling after drug
washout. Furthermore, levetiracetam, but not valproate,
was found to suppress pentylenetetrazole kindling at doses
that did not suppress pentylenetetrazole-induced seizures
[136].
After the initial observation of an antiepileptogenic or
disease-modifying potential of levetiracetam in the kin-
dling model [15], a gene expression analysis was per-
formed to identify the mechanisms responsible for these
effects [137]. Previously described epilepsy-related genes,
such as neuropeptide Y (NPY), thyrotropin-releasing hor-
mone (TRH) and glial fibrillary acidic protein (GFAP),
were upregulated by kindling, and partially normalized by
levetiracetam. Similarly, Husum et al. [138] reported that
the process of amygdala kindling is associated with an
upregulation of hippocampal NPY and brain-derived neu-
rotropic factor (BDNF) which is prevented by levetirac-
etam. In a subsequent study by Matveeva et al. [42], it was
shown that levetiracetam also inhibits the kindling-induced
increase of the synaptic vesicle protein SV2A.
However, several studies showed that levetiracetam did
not prevent epilepsy when administered after an electri-
cally- or chemically-induced SE that induces epileptogen-
esis and, after a latent period, epilepsy with spontaneous
recurrent seizures [139]. This negative outcome of leve-
tiracetam studies in post-SE models was unexpected and
gave rise to critical arguments on study design used for
drug testing in the SE models [140]. Indeed, SE induced by
systemic administration of chemoconvulsants such as
pilocarpine or kainate, or by sustained electrical stimula-
tion of amygdala or hippocampus, may induce too severe
and widespread brain injury for allowing any antiepilep-
togenic or disease-modifying effects of drugs administered
after such SE [139]. Interestingly, Margineanu et al. [141]
reported that, although prophylactic treatment with leve-
tiracetam after a pilocarpine-induced SE did not seem to
prevent development of spontaneous seizures, it com-
pletely prevented the development of hippocampal hyper-
excitability, i.e. increased amplitude of population spikes
recorded in the dentate gyrus and reduced paired-pulse
inhibition in the CA1 area. More recently, Sugaya et al.
[142] reported that the treatment of rats with levetiracetam
over 25 days following SE, induced by intracerebroven-
tricular administration of kainate, reduced the frequency
and duration of electrographic seizures recorded 32 days
after the termination of treatment [142], which is the first
proof that levetiracetam does exert disease-modifying
activity in a post-SE model of TLE.
In contrast to the conflicting results from post-SE stud-
ies, studies in genetic animal models of epilepsy have
consistently shown antiepileptogenic properties of leve-
tiracetam when administered before the developmental
expression of seizure activity [132]. Thus, levetiracetam
was found to exert antiepileptogenic or disease-modifying
effects in SERs [143, 144], indicating that studies on kin-
dling acquisition may be more predictive for such effects
than data from SE models, and that post-SE studies may
lead to false negative data on antiepileptogenic drug
potential [139].
Clinical pilot trials directed by Dr. Pavel Klein (Mid-
Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA)
determined the safety and feasibility of using levetiracetam
to decrease the risk of post-traumatic epilepsy, resulting in
promising data [145–147]. In one of these studies [145], an
open-label, non-randomized study in 126 adults and chil-
dren, assessing the safety, tolerability, and pharmacoki-
netics of levetiracetam, treatment in patients with traumatic
brain injury (TBI) for 1 month, initiated within 8 h of the
injury, showed a non-significant trend toward fewer
patients receiving levetiracetam treatment (11 %) devel-
oping epilepsy after 2 years than those who were untreated
(20 %). A large, controlled epilepsy prevention trial in
patients with TBI is planned. An uncontrolled, retrospec-
tive analysis of patients undergoing craniotomy and treated
postoperatively with either levetiracetam or phenytoin
showed that fewer patients who received levetiracetam
(26 %) developed epilepsy after 1 year than those treated
with phenytoin (36 %), although the difference did not
reach statistical significance [148]. Interestingly, a recent
SV2A Ligands 1071
retrospective analysis of seizure outcome implications of
ASD use in patients who underwent temporal lobectomy
demonstrated perioperative use of levetiracetam to predict
a more favorable outcome [149]. While all ASDs were
equally effective to suppress early (acute symptomatic)
seizures after surgery, at 5 years, patients taking leve-
tiracetam exhibited a substantial ‘seizure freedom advan-
tage’ over other drugs, including carbamazepine,
lamotrigine, oxcarbazepine, phenytoin, and topiramate.
The authors speculated that this might reflect an
antiepileptogenic action of levetiracetam under the
assumption that the late recurrence ([6 months post-sur-
gery) of epilepsy reflects a new epileptogenic process fol-
lowing removal of the original epileptic focus. Overall, the
available preclinical and clinical data indicate that contin-
ued clinical evaluation of the antiepileptogenic potential of
levetiracetam is worthwhile.
In this context, it is noteworthy that the selective, high-
affinity SV2A ligand brivaracetam shows more pronounced
antiepileptogenic effects than levetiracetam in kindling
models in mice [108]. In a rat model of post-SE TLE, in
which SE is induced by intermittent stimulation of the
perforant path, treatment with brivaracetam or a combi-
nation of brivaracetam and diazepam 10 min after estab-
lishment of self-sustained SE reduced the number of
chronic spontaneous recurrent seizures occurring both
6 weeks and 1 year after treatment, indicating a disease-
modifying effect, although the contribution of initial insult
modification cannot be excluded [150]. The favorable
evidence from these initial studies supports the continued
evaluation of the antiepileptogenic potential of
brivaracetam.
7 Conclusions
SV2A represents an integral constituent of synaptic vesicle
membranes in presynaptic terminals and is involved in
vesicle trafficking and exocytosis, which is crucial for
neurotransmission [36]. The SV2A protein contains multi-
ple interacting binding sites that are linked via the confor-
mation of the protein [88]. Levetiracetam was the first ASD
to target SV2A, and thereby revealed that SV2A is involved
in the underlying pathology of certain kinds of epilepsy,
which is supported by various preclinical and clinical
studies showing altered expression of SV2A in epilepsy.
Furthermore, dysfunction of SV2A may potentially be
involved in AD and other types of cognitive impairment,
thus providing novel therapeutic indications to consider for
levetiracetam and its congeners. One of the functional
consequences of levetiracetam binding to the SV2A protein
in brain slices was found to be a reduction in exocytosis
[89]; however, the underlying mechanistic effect of ligand
binding is not fully elucidated. One hypothesis would be
that ligand binding to SV2A would promote/stabilize a
conformation that enables the protein to fulfill a role in
providing seizure protection [88]. The recent development
of negative SV2A modulators, such as UCB0255, which
counteracts the anti-seizure effect of levetiracetam [66],
will help to further clarify how levetiracetam specifically
interacts with SV2A. There is evidence that levetiracetam
may alter short-term synaptic plasticity [89, 91] known to
arise from simultaneous activation of multiple positive
(enhancement) and negative (depression) mechanisms
within presynaptic terminals [93]. Increasing the impact of
depression at excitatory synapses might have potential for
treating epilepsy because more synaptic depression would
dampen excitatory feedback in neural circuitry during
incipient seizures, thus switching the balance between
excitatory and inhibitory synaptic drive to favor inhibition
[93]. The effect of levetiracetam on activity-dependent
synaptic plasticity would also provide an explanation for the
disease-modifying or antiepileptogenic effects of this drug
in both genetic and acquired forms of experimental epi-
lepsy. The recent development of PET ligands for SV2A
allows imaging of this protein in the brain in vivo. This will
hopefully facilitate a further understanding of its role in
epilepsy and other diseases, and enable new and innovative
ways to define the full therapeutic potential of modulating
SV2A function.
Finally, many questions remain to be explored, includ-
ing why SV2A is highly expressed in some brain areas but
absent in others; the differential regulation of SV2A
expression in different models of epilepsy and other
pathologies; and the exact mechanism of action of leve-
tiracetam and its congeners on SV2A. Emerging data,
albeit not as broad as that reported for SV2A, seem to
suggest a potential role of SV2B and SV2C in epilepsy and
other neurodegenerative diseases, and these additional SV2
isoforms could also become novel drug targets. As shown
in this review, the recent availability of SV2A PET ligands
and brivaracetam will enable research to further address the
physiology and pathophysiology of SV2A, as well as the
pharmacology and therapeutic utility of SV2A ligands.
This represents a rapidly evolving field of research that has
the capability to address many of these relevant and
impactful questions in the near future.
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